Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 4 for:    Tadekinig alfa
Previous Study | Return to List | Next Study

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03512314
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : July 22, 2022
Information provided by (Responsible Party):
AB2 Bio Ltd.

Brief Summary:
This is an open-label extension study for patients previously enrolled in the AB2 Bio Ltd. ongoing Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953). This OLE study will evaluate the long-term safety and tolerability of Tadekinig alfa in patients suffering from pediatric monogenic autoinflammatory diseases harboring deleterious mutations of NLRC4 and XIAP.

Condition or disease Intervention/treatment Phase
XIAP Deficiency NLRC4-MAS Drug: Tadekinig alfa Phase 3

Detailed Description:

Pediatric auto-inflammatory conditions related to spontaneous activating mutations of the NLRC4 and with recurrent MAS-like flares with constitutive IL-18 hypersecretion, may require long-term blockade of the IL-18 pathway.

Patients with X-linked inhibitor of apoptosis (XIAP) deficiency and suffering from Hemophagocytic-Lymphohistiocytosis (HLH), a MAS-like syndrome, also show high levels of serum IL-18 and may benefit from IL-18 blockade treatment until a curative hematopoietic stem cell transplantation can be performed The safety of IL-18 blockade during long-term periods is of major interest for the treatment of these patients

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
Actual Study Start Date : January 24, 2018
Estimated Primary Completion Date : November 30, 2023
Estimated Study Completion Date : January 30, 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tadekinig alfa
Active drug treatment during 26 weeks
Drug: Tadekinig alfa
Open label, 26 weeks on Tadekinig alfa treatment.
Other Name: r-hIL-18BP

Primary Outcome Measures :
  1. Reports of adverse events [ Time Frame: 26 weeks ]
    The incidence, nature and severity of AEs will be reported

  2. Reports of abnormal physical examination [ Time Frame: 26 weeks ]
    Measurements will be done using the modified Auto-inflammatory Disease Activity Index (mAIDAI) including multiple measurements aggregated as 1 / 0.

  3. Reports of abnormal laboratory results [ Time Frame: 26 weeks ]
    Report of clinically significant abnormal laboratory results (i.eSerum CRP (ug/mL), Serum Ferritin (ng/mL). and any other abnormal lab results

  4. Immunogenicity evaluation [ Time Frame: 26 weeks ]
    Generation of anti-recombinant human Interleukin-18 Binding Protein (anti-rhIL-18BP) antibodies

  5. Evaluation of the local tolerability at the injection site [ Time Frame: 26 weeks ]
    Evaluation will be done based on the Local Tolerability Index where the patients will be asked to assess the degree of pain, redness, swelling, bruising, tenderness and itching, they are experiencing from each injection.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: (both criteria must be met)

  1. Patients have participated in AB2 Bio ltd. Phase III clinical trial NLRC4/XIAP.2016.001 (IND N° 127953) by one of the following mechanisms : a) Patients that have completed the first 18-week RCT phase of the preceding clinical trial but were not eligible for the RW phase due to flare symptoms. Or b) Patients that completed the first 18-week RCT phase and completed the RW phase of the preceding clinical trial. Or c) Patients who have exited either the RCT or RW phase of the preceding clinical trial due to treatment failure requiring rescue immunosuppression. Such patients must wait a minimum of 4 weeks after treatment discontinuation from the preceding clinical trial before enrolling in this OLE. If patients do not consent to enroll in the OLE after their early termination in the main study, they will be asked to continue with the planned visits of the main study
  2. Women of childbearing potential with negative urine pregnancy test (UPT) at all visits

Exclusion Criteria:

  1. Patients may not enter the OLE if they voluntarily withdrew from RCT or RW study or if the time period between participation exceeds 3 months
  2. Evidence or history of malignancy
  3. Evidence of invasive or life-threatening infection
  4. History of tuberculosis
  5. Life-threatening bleeding within 2 weeks of screening
  6. Vaccination with a live vaccine within the previous 3 months
  7. Evidence of severe organ compromise including but not limited to: (see details in the protocol)
  8. Pregnant or breastfeeding females
  9. Inability to follow highly effective birth control recommendations during the study and until 1 month after the end of the treatment.
  10. Inability to provide informed consent, and also assent if applicable
  11. Life expectancy less than 4 weeks
  12. Concomitant use of other immunosuppression except NSAIDs, glucocorticoids, cyclosporine, tacrolimus, IL-1 inhibitors (Anakinra, Canakinumab, or Rilonacept)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03512314

Layout table for location contacts
Contact: Eduardo Schiffrin, MD +41 21 694 00 43
Contact: Friederike Stein, PhD +41 21 694 00 40

Layout table for location information
United States, California
UCSD _ Department of Pediatrics / Rady Children's Hospital Recruiting
La Jolla, California, United States, 92056
Contact: Harold Hoffman, Dr.    858-966-1700 ext 3422      
United States, Florida
Shands Children's Hospital Completed
Gainesville, Florida, United States, 32610
United States, Georgia
Children's Healthcare of Atlanta at Egleston Recruiting
Atlanta, Georgia, United States, 30322
Contact: Shanmuganathan Chandrakasan, MD    404-272-8877      
United States, Massachusetts
Boston Children's Hospital Not yet recruiting
Boston, Massachusetts, United States, 02115
Contact: Fatma Dedeoglu, Dr.    617-355-6117      
United States, Ohio
Cincinnati Children's Hospital Medical Center Recruiting
Cincinnati, Ohio, United States, 45229
Contact: Rebecca Marsh, Dr.    513-803-9063      
United States, Pennsylvania
Children Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Ed Behrens, Dr.    267-426-0142   
Children's Hospital of Pittsburgh of UPMC Completed
Pittsburgh, Pennsylvania, United States, 15224
United States, Texas
Texas Children's Hospital _ Baylor College of Medicine Recruiting
Houston, Texas, United States, 77030
Contact: Lisa Forbes, Dr.    832-824-1319      
Canada, Ontario
The Hospital for Sick Children Recruiting
Toronto, Ontario, Canada, ON M5G 1X8
Contact: Ronald Laxer, M.D.    416-813-5068      
CHU Sainte-Justine Recruiting
Montréal, Canada
Contact: Julie Barsalou, MD    514-345-4931      
Universitätsklinikum Freiburg, Centrum für Chronische Immundefizienz (CCI) - Paediatric Unit Not yet recruiting
Freiburg, Baden-Württemberg, Germany, 79106
Contact: Stephan Ehl, MD    00497612707755   
Sponsors and Collaborators
AB2 Bio Ltd.
Layout table for investigator information
Principal Investigator: Eduard Behrens, MD Children Hospital of Philadelphia
Layout table for additonal information
Responsible Party: AB2 Bio Ltd. Identifier: NCT03512314    
Other Study ID Numbers: OLE-NLRC4/XIAP.2016.001
First Posted: April 30, 2018    Key Record Dates
Last Update Posted: July 22, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: This information will be provided soon

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Genetic Diseases, X-Linked
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Genetic Diseases, Inborn